Potential markers that complement expression of CA125 in epithelial ovarian cancer
Top Cited Papers
- 1 November 2005
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 99 (2), 267-277
- https://doi.org/10.1016/j.ygyno.2005.06.040
Abstract
No abstract availableThis publication has 47 references indexed in Scilit:
- Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal DistributionsJournal of Clinical Oncology, 2004
- Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinomaGynecologic Oncology, 2004
- Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancerGynecologic Oncology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal WomenJournal of Clinical Oncology, 2003
- OsteopontinCritical Reviews in Oral Biology & Medicine, 2000
- Immunohistochemical Characterization of 22 Monoclonal Antibodies against the CA125 Antigen: 2nd Report from the ISOBM TD-1 WorkshopTumor Biology, 1996
- Prospective on ovarian cancer: Why prevent?Journal of Cellular Biochemistry, 1995
- Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging.BMJ, 1993
- Comparison Between Tissue and Serum Content of CA 125, CA 19–9, and Carcinoembryonic Antigen in Ovarian TumorsInternational Journal of Gynecological Pathology, 1989